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Protein lysine methyltransferases are important
regulators of epigenetic signaling. These enzymes
catalyze the transfer of donor methyl groups from
S-adenosylmethionine to specific acceptor lysines
on histones, leading to changes in chromatin struc-
ture and transcriptional regulation. These enzymes
also methylate nonhistone protein substrates,
revealing an additional mechanism to regulate
cellular physiology. The oncogenic protein SMYD2
represses the functional activities of the tumor
suppressor proteins p53 and Rb, making it an attrac-
tive drug target. Here we report the discovery of
AZ505, a potent and selective inhibitor of SMYD2
that was identified from a high throughput chemical
screen. We also present the crystal structures of
SMYD2 with p53 substrate and product peptides,
and notably, in complex with AZ505. This substrate
competitive inhibitor is bound in the peptide binding
groove of SMYD2. These results have implications
for the development of SMYD2 inhibitors, and indi-
cate the potential for developing novel therapies
targeting this target class.
INTRODUCTION
Heritable states, not encoded by DNA, are referred to as epige-
netic. Epigenetic marks are propagated to daughter cells to
maintain heritable differentiated phenotypes (Bonasio et al.,
2010). Multiple lines of evidence implicate the deregulation of
histone methylation in the initiation, evolution, and maintenance
of cancer and other diseases (Tsai and Baylin, 2011). Indeed,
many protein lysine methyltransferases act as classical onco-
genes that are capable of driving cellular transformation (Okada
et al., 2005; Karanikolas et al., 2009). These enzymes are attrac-
tive drug targets that are being actively pursued by the pharma-
ceutical industry (Copeland et al., 2009).
The human genome encodes 50 SET-domain containing
proteins (Albert and Helin, 2010). Collectively, these enzymes
catalyze the transfer of a donor methyl group from S-adenosyl-1262 Structure 19, 1262–1273, September 7, 2011 ª2011 Elsevier Ltmethionine (SAM) to acceptor lysine residues on protein
substrates. Methylation at discrete positions on histones can
have repressive or activating effects on transcription (Bernstein
et al., 2006; Pan et al., 2007). More recently, protein lysine meth-
yltransferases have been shown to methylate nonhistone protein
substrates; influencing their stability, cellular localization, and
function (Tsai and Baylin, 2011).
The human SMYD (SET and MYND domain-containing
protein) family of protein lysine methyltransferases contains
five members (SMYD1-5) (Brown et al., 2006), and defined roles
in development and cancer have been established. For example,
disruption of SMYD1 leads to perturbed cardiac morphogenesis
and embryonic lethality (Gottlieb et al., 2002), whereas SMYD3
has been shown to be involved in cancer cell proliferation, and
is overexpressed in hepatocellular, colorectal, and breast carci-
nomas (Hamamoto et al., 2004, 2006).
SMYD2 has been shown to methylate both histone (H2B, H3,
and H4) and nonhistone protein substrates, including the tumor
suppressor proteins p53 and Rb (Brown et al., 2006; Huang
et al., 2006; Abu-Farha et al., 2008; Wu et al., 2011). Methylation
of K370 of p53 impairs its ability to bind to the promoters of
target genes (Chuikov et al., 2004; Huang et al., 2006). Methyla-
tion of Rb at residue K860 generates an epitope that is selectively
recognized by the transcriptional repressor L3MBTL1 (Saddic
et al., 2010). This may provide a mechanism for recruiting
L3MBTL1 to the promoters of specific Rb/E2F target genes,
thereby repressing their activities. In addition to these estab-
lished biological pathways, the SMYD2 gene lies in the 1q32-
q41 region, which is frequently amplified in esophageal squa-
mous cell carcinoma (ESCC) and other solid tumors (Rooney
et al., 1999; Komatsu et al., 2009). Overexpression of SMYD2
is observed in the esophageal cell line KYSE150, and in ESCC
primary tumor samples (Komatsu et al., 2009). Genetic knock-
down of SMYD2 leads to decreased ESCC cell proliferation.
Given the activity of SMYD2 in ESCC cells and that its protein
substrates have been implicated in gene transcription, apoptosis
and cell cycle regulation, we were interested in developing small
molecule inhibitors of SMYD2. Here we report the discovery and
characterization of AZ505, a potent inhibitor of SMYD2. We also
present the crystal structures of SMYD2 with p53 substrate and
product peptides, and with AZ505. These results have clear
implications for the development of SMYD2 inhibitors, and
further enhance the biological understanding of this emerging
cancer target.d All rights reserved
Figure 1. Discovery of AZ505
(A) HTS and hit validation cascade.
(B) AlphaScreen technology.
(C) Dose response curve for AZ505.
(D) AZ505 chemical structure.
(E) Selectivity profile of AZ505.
See also Figure S1.
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HTS Assay and Hit Validation
To determine optimal HTS assay conditions, we profiled the
enzymatic activity of SMYD2 across a panel of standard buffers
using peptides derived from two characterized substrates,
residue K36 of histone H3 (Brown et al., 2006) and residue
K370 of the transcription factor p53 (Huang et al., 2006). A
detailed analysis of the substrate profile of SMYD2 and the
development of the assay conditions utilized in this study are
presented elsewhere (Wu et al., 2011). Our enzymatic profiling
showed that SMYD2 had maximal activity in Tris-HCl (pH 9.0)
with low ionic strength buffer using a nonhistone substrate
peptide spanning residues 361–380 of the C-terminal regulatory
domain of p53. A small amount of detergent was also included in
the assay buffer to increase protein stability at low nM enzyme
concentrations and to minimize compound-driven protein
aggregation (Feng et al., 2005). In developing the HTS assay,
we characterized SMYD2 by steady-state kinetics and deter-
mined the apparent Km values for SAMand the substrate peptide
to be 100 nM and 700 nM, respectively. The stoichiometry of
SAM binding to SMYD2 as derived by ITC was far less than the
expected 1:1 ratio, indicating that the recombinant protein used
for the HTS assaywas predominantly SAM-bound (see Figure S1
available online). Native mass spectrometry data also supported
this observation (data not shown). Unfortunately, wewere unable
to remove the bound cofactor and retain protein stability. For this
assay, the SAM concentration was set to its apparent Km and the
peptide concentration was set to several-fold below its apparent
Km to avoid the Hook effect. Under these assay conditions, there
is a reduced probability of identifying uncompetitive inhibitors for
peptide substrates and SAM-competitive inhibitors of SMYD2.Structure 19, 1262–12AlphaScreen technology was used to screen a 1.23 million
compound library for SMYD2 inhibitors, producing a hit rate of
1.2% (Eglen et al., 2008). In our hands, AlphaScreen technology
has a high false-positive hit rate and is prone to compound inter-
ference. For this reason, an effective hit validation cascade was
designed (Figures 1A and 1B).
An artifact counter screen was developed to identify false-
positive hits resulting from compound interference. Five con-
centration point IC50 curves were determined for 1200 com-
pounds using an orthogonal radiometric SPA assay and an
artifact assay. Using this process, 25 chemically attractive
series with IC50 values <40 mM and dozens of singleton hits
were identified. Up to 10 near neighbors were collected for
each chemical series, and 10 concentration point IC50 curves
were determined to investigate the structure-activity relation-
ships for the hits identified from the primary screen. Compounds
that passed the artifact assays and had similar potencies in
an orthogonal assay should be free of false-positive hits
generated from compound interference. However, false-posi-
tives caused by compound-induced protein aggregation still
needed to be removed from the primary screening hits. We
examined the reproducibility of the IC50 values and the
associated Hill slopes for all 25 chemical series. A ratio test
was used to eliminate nonspecific promiscuous compounds
that showed enzyme concentration-dependent and time-
dependent inhibition of SMYD2. However, all compounds with
potencies <1 mM were retained irrespective of their ratio test.
Of the 25 chemical series evaluated by this method, the com-
pound designated as AZ505 [N-cyclohexyl-3-(3,4-dichlorophe-
nethylamino)-N-(2-(2-(5-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b]
[1,4]oxazin-8-yl)ethylamino)ethyl)propanamide] showed an IC50
of 0.12 mM (Figures 1C and 1D). Moreover, AZ505 failed to73, September 7, 2011 ª2011 Elsevier Ltd All rights reserved 1263
Figure 2. Biophysical Characterization of AZ505
(A) ITC data showing AZ505 binding to SMYD2.
(B) Kinetic analysis of AZ505 binding to SMYD2. Duplicate data points were
averaged and subtracted from radiolabeled SAM background counts at each
Structure
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1264 Structure 19, 1262–1273, September 7, 2011 ª2011 Elsevier Ltinhibit the enzymatic activities of a panel of protein lysinemethyl-
transferases (Figure 1E).
Following our hit validation cascade, 20 compounds were
nominated for ITC binding studies. We were able to confirm
binding for 6 of 20 compounds, with the most potent compound
(AZ505) having a calculated Kd of 0.5 mM (DH
 = 3.4 kCal/mol,
TDS = 5 kCal/mol and N = 1) (Figure 2A). In contrast, the calcu-
lated Kd for the p53 substrate peptide was 3.7 mM (Figure S2).
Comparing the DH and TDS values shows that AZ505 binding
to SMYD2 is driven primarily by entropy, which often suggests
that binding is mediated by hydrophobic interactions with few
specific hydrogen bonds (Ladbury, 2010).
The kinetics of AZ505 binding to SMYD2 were determined by
inhibition kinetic experiments using filter binding assays. Anal-
ysis of the double-reciprocal plot of the initial velocities against
substrate concentrations indicates that AZ505 binding to
SMYD2 is competitive with the peptide substrate and uncompet-
itive with the cofactor (Figure 2B). The inhibition constant for
AZ505 was determined to be 0.30 mM using Michaelis-Menten
kinetics. Steady-state kinetic and product inhibition experiments
show that SMYD2 catalyzes themonomethylation of this peptide
substrate by a rapid equilibrium random Bi Bi mechanism
(detailed analysis is presented in Wu et al. [2011]) (Table S1).
Similar mechanisms have been observed with other protein
lysine methyltransferases (Patnaik et al., 2004; Chin et al., 2006).
Overall Structure
To understand the structural basis of nonhistone substrate
recognition and inhibitor binding, a series of SMYD2 crystal
structures were determined (Table 1). The X-ray crystal structure
of full-length human SMYD2 was solved by SAD phasing using
the anomalous signal from intrinsically bound zinc. Sequential
rounds of model building and refinement produced models for
SMYD2 that contain all residues except for the first four
N-terminal residues.
The overall structure of SMYD2 is composed of five structur-
ally distinct domains, which together form two large lobes that
are separated by a deep groove (Figures 3A and 3B). Residues
1–282 comprise the first four domains and the N-terminal lobe
of SMYD2. Specifically, residues 1–49 form the S-sequence
(the N-terminal portion of the split catalytic SET domain); resi-
dues 50–98 form the MYND domain, which is a conserved
zinc-finger motif that mediates protein-protein interaction with
the cytoskeleton associated protein EPB41L3 (Abu-Farha et al.,
2008); residues 101–182 form the insertion SET domain (I-SET);
residues 183–245 form the core SET domain (the C-terminal
portion of the split catalytic SET domain); and residues 246–
282 form the cysteine-rich post-SET domain (Figures 3A and
3B). Expectedly, the overall arrangement of these four domains
has been observed in other protein lysine methyltransferases.SAM concentration. Normalized counts were converted to reaction product
concentrations by a standard curve of measured counts per second for known
molar quantities of radiolabeled SAM, ensuring that the measured range is
sufficiently broad to cover the expected counts from the experimental data.
To confirm the accuracy of this method, a standard curve of measured
counts for varying molar quantities of radiolabeled p53 product peptide,
producing <2-fold difference in slope.
See also Figure S2 and Table S1.
d All rights reserved
Table 1. Crystallographic and Refinement Statistics
Data Set SAM SAM + AZ505 SAM + p53 SAH + Methylated p53
Space group I4 I4 I4 I4
Unit cell dimensions (A˚)
a = b, c; a = b = g = 90 154.22, 53.07 155.86, 52.83 156.41, 52.89 153.83, 52.72
Beam line ID 14-4 ID 23-1 ID 23-1 ID 23-1
Wavelength (A˚) 1.2805 1.0723 1.0000 0.9762
Resolution (A˚) 50–3.0 55–2.4 110–2.8 108–2.3
Unique reflections 11821 (119) 24403 (3512) 15184 (2193) 27434 (3957)
Multiplicity 17.5 (17.6) 3.7 (3.7) 4.0 (4.1) 4.0 (3.7)
Completeness (%) 100 (100) 99.7 (99.8) 99.8 (100) 98.8 (98.4)
<I/sI> 24.2 (7.2) 12.9 (2.7) 15.4 (2.5) 16.6 (2.3)
Rmerge (%)
a 0.123 (0.521) 0.072 (0.49) 0.066 (0.489) 0.050 (0.49)
Phasing power 0.750 — — —
Figure of merit after SHARP refinement 0.236 — — —
Figure of merit after density modification 0.905 — — —
Refinement
Rwork
b/Rfree
c (%) 19.3/20.9 17.3/19.8 17.1/20.0 18.3/21.0
Water — 160 13 120
Cofactor 1 (SAM) 1 (SAM) 1 (SAM) 1 (SAH)
Inhibitor — 1 — —
Peptide — — 1 1
Root-mean-square deviation from ideal
Bond lengths (A˚) 0.010 0.010 0.10 0.010
Bond angles () 1.25 1.12 1.12 1.12
Average B-factor (A˚2)
Protein 82 47 65 54
Cofactor 61 37 50 38
Inhibitor — 52 — —
Peptide — — 71 72
aRmerge = SjI  <I>j/SI, where I is the integrated intensity of a given reflection and <I> is the average intensity of multiple observations of symmetry-
related reflections.
bRwork = SjFo  Fcj/SFo), where Fo and Fc are observed and calculated structure factors.
c Rfree was calculated from a 5% subset of reflections that were excluded from the refinement. Brackets indicate highest resolution shell.
Structure
Structural Basis of SMYD2 InhibitionThree zinc ions are also bound to the N-terminal lobe. A cluster of
three cysteine residues (C262, C264, and C267) from the post-
SET domain along with residue C209 from the core SET domain
coordinate a single zinc ion, forming a knotted pseudoloop that
connects the N- and C-terminal lobes of SMYD2. A similar struc-
tural feature is found in SMYD1 (Sirinupong et al., 2010) andStructure 19, 1262–12SMYD3 (Sirinupong et al., 2011), and in other protein lysine
methyltransferases including G9a and SET7/9 (Cheng et al.,
2005; Chang et al., 2009; Wu et al., 2010).
The SMYD proteins have a unique split SET domain architec-
ture that catalyzes lysine methylation. The S-sequence and the
core SET domain combine to form the catalytically active SETFigure 3. Overall Structure
(A) The view is given directly above the pronounced
surface groove that separates the N- and C-terminal lobes
of SMYD2.
(B) The view has been rotated by 90. The S-sequence is
cyan; the MYND domain is red; the I-SET domain is blue;
the core SET domain is green; the post-SET domain is
orange; and the C-terminal domain is yellow. Three
coordinated zinc ions are shown as purple spheres. The
cofactor SAM has white carbon atoms, red oxygen atoms,
blue nitrogen atoms, and orange sulfur atoms.
73, September 7, 2011 ª2011 Elsevier Ltd All rights reserved 1265
Figure 4. Structural Comparisons
(A) The human SMYD2 structure is green whereas mouse SMYD1 is cyan.
(B) The human SMYD2 structure is green whereas human SMYD3 is magenta.
Structure
Structural Basis of SMYD2 Inhibitiondomain of SMYD2. The MYND, I-SET, and post-SET domains
physically surround the core SET domain. The C-terminal lobe
of SMYD2 (residues 283–433) is a twisted seven a-helical bundle
(Figures 3A and 3B). A search against all structures deposited in
the Protein Data Bank (PDB) shows that the fold of the C-terminal
domain of SMYD2 has been observed previously. However, this
domain appears to be unique to the SMYD protein family as no
other protein lysine methyltransferases were identified.
The recently determined structures of mouse SMYD1 (Sirinu-
pong et al., 2010) and human SMYD3 (Sirinupong et al., 2011)
have a similar overall fold (Figures 4A and 4B). Comparing the
structure of SMYD2 to those of SMYD1 and SMYD3 yields
a root-mean-square deviation for 372 aligned residues is
2.99 A˚ for SMYD1 (28% sequence identity); and is 2.68 A˚ for
365 aligned residues for SMYD3 (31% sequence identity) (Krissi-
nel, 2007). However, the relative arrangements of the N- and
C-terminal lobes differ between these three SMYD family
members, and hence the size and shape of the peptide binding
groove differs. We do not observe any significant conformational
changes on binding in the binary and ternary complexeswith p53
substrate and product peptides, or AZ505.
Cofactor Binding Site
In this study, SMYD2 was cocrystallized with the cofactor SAM
and the structure was determined at 3 A˚ resolution (Table 1).1266 Structure 19, 1262–1273, September 7, 2011 ª2011 Elsevier LtThe structure shows one SAM molecule bound to the protein,
and that the cofactor binding site is positioned at the bottom of
the deep surface groove that separates the N- and C-terminal
lobes of SMYD2.
All but one protein lysine methyltransferase (DOT1L) contains
a SET domain, the canonical structural motif that is required
for lysine methylation. The catalytic SET domain of SMYD2 is
unique as it is formed by two noncontiguous regions of primary
sequence, the S-sequence and the core SET domain are
separated by the MYND and I-SET domains. The catalytic SET
domain of SMYD proteins contain three highly conserved
sequence motifs that contribute to SAM binding (Cheng
et al., 2005). They are the GxG motif (residues 18–20 of the
S-sequence), the NHxCxPN motif (residues 206–212 of the
core SET domain), and the GEExxxxY motif (residues 233–240
of the core SET domain). These sequencemotifs alongwith other
residues from the S-sequence, the I-SET domain and the core
SET domain, and residues from the post-SET domain contribute
main chain and side chains atoms to form this nearly enclosed
electronegative binding site (Figure 5A). Numerous electrostatic
and hydrophobic packing interactions are formed with each
chemical moiety of SAM (Figure 5B). The NHxCxPN motif forms
extensive interactions with the cofactor. The structural arrange-
ment of this highly intricate binding site aligns the donor methyl
group of SAM so that it projects into the lysine-binding channel
of SMYD2. This binding mode is broadly conserved among
structurally defined SET domain-containing enzymes (Cheng
et al., 2005; Wu et al., 2010). However, the bound SAM cofactor
in these enzymes is more surface-exposed and is less highly
coordinated than in the SYMD protein family (SMYD1, SMYD2,
and SMYD3) (Campagna-Slater et al., 2011).
Deletion of either the NHxCxPN or GEExxxxYmotifs abolishes
themethyltransferase activity of SMYD2 (Abu-Farha et al., 2008).
It has been previously reported that the S-sequence of SMYD3
has an inhibitory effect on its enzymatic activity, and that its
removal or perturbation enhances activity (Silva et al., 2008). In
contrast, a double mutant (G18/20A) within the GxG motif
showed significantly decreased activity of SMYD2 (Wu et al.,
2011). The SMYD2 structure reveals that the S-sequence forms
an integral part of the SAM binding pocket, and that the GxG
motif forms direct electrostatic interactions with the methionine
moiety of the SAM cofactor (Figure 5B). Given the functional
and structural importance of this region, removing the first 13
residues would clearly disrupt the structural integrity of the
cofactor binding site. Indeed, removing the first 13 residues of
the S-sequence reduced activity.
p53 Binding Site
We cocrystallized SMYD2 in the presence of a short peptide
spanning residues 366–378 of the C-terminal regulatory domain
of p53 (366-SSHLKSKKGQSTS-378), and determined the struc-
ture of the ternary complex at 2.85 A˚ resolution (Table 1). Only the
central six residues of the p53 peptide (369-LKSKKG-374) were
visible in the electron density map. The p53 substrate peptide is
bound at the base of the prominent electronegative groove sepa-
rating the N- and C-terminal lobes of SMYD2. Residues from the
core SET, I-SET, and post-SET domains, along with residues
from the C-terminal lobe comprise the p53 peptide binding site
(Figure 5C).d All rights reserved
Figure 5. Cofactor and Peptide Binding Sites
(A) Cofactor binding site (top) and with its molecular surface colored by electrostatic potential (bottom).
(B) Close-up of the cofactor binding site. Electrostatic interactions formed between SAM and main chain and side chain atoms of SMYD2 are shown as black
dashed lines.
(C) The p53 peptide binding site of SMYD2 (top) and with its molecular surface colored by electrostatic potential (bottom).
(D) Close-up of the p53 peptide binding site. Electrostatic interactions formed between the monomethylated p53 peptide andmain chain and side chain atoms of
SMYD2 are shown as black dashed lines. In these panels, themolecular surface has been colored according to electrostatic potential (calculated by APBS [Baker
et al., 2001]) with blue and red corresponding to +10 kT and10 kT, respectively. Black labels indicate SMYD2 residueswhereas red labels indicate residues from
the p53 peptide.
Structure
Structural Basis of SMYD2 InhibitionThe bound p53 peptide is aligned with residues 240–242 of
the loop that immediately precedes the post-SET domain,
generating a short two-stranded parallel b sheet with strand b8
of the core SET domain (Figure 5D). A similar peptide binding
mode has been observed in other SET enzymes (Cheng et al.,Structure 19, 1262–122005; Couture et al., 2006; Wu et al., 2010). The acceptor lysine
residue K370 of the p53 peptide is positioned deep within the
lysine-binding channel of SMYD2, and its 3-amino group is
placed 2.6 A˚ from the donor methyl group of SAM. A narrow
circular access port links opposite sides of the catalytic SET73, September 7, 2011 ª2011 Elsevier Ltd All rights reserved 1267
Figure 6. AZ505 Binding Site
(A) AZ505 binding site. The final 2Fo-Fc electron density map surrounding the inhibitor is shown as bluemesh (contoured at 1s). Water molecules are red spheres.
Electrostatic interactions formed between AZ505 and main chain and side chain atoms of SMYD2 are shown as black dashed lines.
(B) Electrostatic surface of the AZ505 binding site.
(C) Close-up of the p53 peptide and AZ505 binding sites of SMYD2.
(D) Partially overlapping binding sites. In these panels, the molecular surface has been colored according to electrostatic potential with blue and red corre-
sponding to +10 kT and 10 kT, respectively.
(E) Chemical structures of BIX-01294, E72 (a BIX-01294 analog) and AZ505. The red highlighting indicates the portion of the inhibitor that is positioned with the
lysine-binding channel.
Structure
Structural Basis of SMYD2 Inhibitiondomain. The donor methyl of SAM is on one side, and the
acceptor lysine is on the other. Residue K370 occupies a
hydrophobic, mostly aromatic cavity with the 3-amino group
oriented by the hydroxyl groups of two highly conserved tyrosine
residues (Y240 and Y258) and numerous main chain carbonyls
(Figure 5D). Comparing the lysine-binding channels of SMYD1,
SMYD2, and SMYD3 reveals similarities between these family
members.
By incubating the binary complex of SMYD2 and SAMwith the
p53 substrate peptide for an extended time prior to mixing with
the crystallization solution, the structure of a ternary complex
of SMYD2 with a monomethylated p53 product peptide and
the cofactor SAH was determined at 2.30 A˚ resolution (Table
1). The refined electron density map of this complex show unam-
biguous electron density for a single methyl group linked to the
3-amino group of residue K370 and the absence of the methyl
group on the cofactor, indicating that SAM had been converted
to SAH. The transferred methyl group is aligned 3.45 A˚ away
from the sulfur of SAH. There is well resolved electron density
for the central five residues of the p53 peptide (369-LKSKK-
373). No significant conformational changes occur within
SMYD2 or the p53 peptide following the methylation reaction.1268 Structure 19, 1262–1273, September 7, 2011 ª2011 Elsevier LtInhibitor Binding Site
SMYD2 was cocrystallized with the most potent inhibitor identi-
fied from the high throughput chemical screen (ITC derived Kd of
0.5 mM). The structure of the ternary complex of SMYD2 with the
cofactor SAM and AZ505 was determined at 2.42 A˚ resolution
(Table 1), and the refined electron density map shows unambig-
uous electron density for AZ505 (Figure 6A).
The structure of the ternary complex reveals that a single
AZ505 molecule is bound in the peptide binding groove of
SMYD2 (Figure 6B). This observation is supported by the kinetic
analysis showing that AZ505 binding to SMYD2 was competitive
with the peptide substrate (Figure 2B). ITC binding studies
suggested that AZ505 binding was mediated by hydrophobic
interactions with few specific hydrogen bonds (Figure 2A). The
structure of the ternary complex supports these observations.
AZ505 is composed of three distinct moieties: benzooxazi-
none, cyclohexyl, and dichlorophenethyl substituents (Figures
1D and 6E). The benzooxazinone group is positioned deepwithin
the lysine-binding channel of SMYD2, and forms an intricate
series of electrostatic and hydrophobic packing interactions
with the donor methyl group of SAM, and main chain and side
chain atoms of SMYD2 (Figure 6A). The ketone oxygen of thed All rights reserved
Structure
Structural Basis of SMYD2 Inhibitionbenzooxazinone moiety is placed 2.8 A˚ from the donor methyl
of SAM. The hydroxyl substituent and the ring amine nitrogen
jointly coordinate awatermolecule, whichmediates electrostatic
interactions with the backbone carbonyl oxygens of residues
V202 and M205 from the core SET domain. On the opposing
side of the benzooxazinone ring, the ether oxygen is coordinated
by residue Y258 from the post-SET domain. A highly coordinated
water molecule bridges additional interactions between the
ether oxygen and the amine linker of AZ505, and the backbone
carbonyls of residues N180 and G183 from the I-SET domain
along with residue Y258 from the post-SET domain. This binding
mode is supported by the kinetic data showing that AZ505
binding to SMYD2 is dependent on the presence of SAM
(Figure 2B).
The cyclohexyl group of AZ505 is positioned in a primary
hydrophobic pocket that is formed at the interface of the core
SET and I-SET domains, which is also occupied by residue
L369 of the p53 peptide (Figure 6C). The amine linker connecting
the cyclohexyl and dichlorophenethyl elements of AZ505 forms
a hydrogen bond with the side chain of residue N180 from the
I-SET domain. Comparing the orientation of this residue shows
it rotates andmoves toward the amine linker to form a 3.3 A˚ elec-
trostatic interaction with AZ505 (Figure 6A). This change also
leads to the formation of a 2.7 A˚ hydrogen bond with the
backbone carbonyl oxygen of residue F184 from the core SET
domain, and a water-bridged interaction with the carboxylate
of residue D152 from the I-SET domain. AZ505 has an IC50 value
of 0.12 mM against SMYD2 (Figure 1E), and has no potency
against SMYD3. Comparing the structures of SMYD2 and
SMYD3 shows that residue V195 physically restricts access to
the primary hydrophobic pocket in SMYD3, which is in agree-
ment with the selectivity profile of AZ505.
Perhaps the most interesting feature of the AZ505 binding
mode is that the dichlorophenethyl moiety of the inhibitor
extends across the peptide binding groove of SMYD2, and is
inserted into a secondary hydrophobic pocket adjacent to the
cofactor binding site that is formed by residues from the I-SET
and post-SET domains (Figures 6A and 6C). The majority of
the protein-inhibitor interactions within this pocket are formed
by hydrophobic packing interactions, however, several water-
mediated electrostatic interactions to main chain carbonyls are
also observed (Figure 6A). Residues from the post-SET domain,
which form electrostatic and hydrophobic interactions with the
adenosyl group of SAM, also make contacts with the dichloro-
phenethyl moiety of AZ505. The secondary hydrophobic pocket
is adjacent to the SAM binding site, and residues that form elec-
trostatic interactions with the adenosyl group of SAM also make
contacts with the dichlorophenethyl moiety of AZ505 (Figure 6A).
This observation suggests the possibility of cooperativity, as the
presence of SAM may contribute to the binding of AZ505.
Comparing the locations of the p53 peptide and AZ505
binding sites of SMYD2 illustrate that these regions are partially
overlapped (Figures 6C and 6D). Although the acceptor lysine
residue of the p53 peptide and the larger more rigid benzooxazi-
none moiety of AZ505 are positioned within the lysine-binding
channel, their relative position and detailed interactions differ.
This result clearly demonstrates the plasticity of the lysine-
binding channel of SMYD2 as these groups share no structural
or chemical similarities. Beyond the lysine-binding channel, resi-Structure 19, 1262–12dues S371, K372, and K373 of the p53 peptide form electrostatic
interactions withmain chain and side chain atoms from the I-SET
and core SET domains, and residues from the C-terminal lobe
of SMYD2 (Figure 6A). AZ505 does not access these regions of
the peptide binding groove (Figures 6C and 6D). However,
residue L369 of the p53 peptide and the cyclohexyl group of
AZ505 both occupy the primary hydrophobic pocket, albeit at
different depths (Figure 6C). All residues preceding residue
L369 of the bound p53 peptide are presumably highly flexible
and could not be modeled. These observations suggest that
the p53 peptide does not access the secondary hydrophobic
pocket of SMYD2.
DISCUSSION
Protein lysine methyltransferases have emerged as attractive
targets for drug discovery, and there are intensive ongoing
efforts to identify chemical starting points for this novel class of
enzymes. Given the activity of SMYD2 in ESCC cells, and that
its protein substrates, including the key tumor suppressors p53
and Rb have been implicated in gene transcription, apoptosis,
and cell cycle regulation, we were interested in developing small
molecule inhibitors of SMYD2. Here we report the results of
a successful high throughput chemical screen to identify small
molecules that inhibit the enzymatic activity of SMYD2. Prelimi-
nary data shows that AZ505 inhibits SMYD2-mediated methyla-
tion in cells (Figure S3), and further experiments are underway to
investigate to effect of AZ505 on p53 activity.
Under our assay conditions, we anticipated to identify
substrate-competitive compounds. By analogy to ATP-compet-
itive protein kinase inhibitors, SAM-competitive inhibitors could
potentially be used as chemical leads for other SET domain-
containing enzymes. No SAM-competitive compounds were
identified in the six distinct chemical series that were validated
by ITC. The most potent of the substrate-competitive com-
pounds was AZ505. Interestingly, the only other protein lysine
methyltransferase inhibitor identified thus far is BIX-01294 or
close derivatives thereof, which are also bound in the substrate
binding groove. These results suggest that it might be more
feasible to identify and develop substrate-competitive inhibitors
for this target class.
It has been suggested that differences in the relative positions
of the N- and C-terminal lobes of SMYD1 and SMYD3 define the
open and closed conformations of SMYD proteins, and that
protein substrate binding drives conformational changes that
involve multiple hinge-like movements, which form the structural
basis of an auto-inhibition mechanism (Sirinupong et al., 2010,
2011). In the series of SMYD2 structures described here—binary
and ternary complexes with p53 substrate and monomethylated
p53 product peptides, and potent small molecule inhibitor—no
such conformational changes were observed.
The methyltransferase activity of SMYD2 is pH-dependent
(Wu et al., 2011), which is in agreement with the notion that
protein lysine methyltransferases utilize the basicity of their
active sites to facilitate the deprotonation-methylation reaction
(Zhang and Bruice, 2008). The aromatic residues lining the inte-
rior surface of the lysine-binding channel regulate the catalytic
activity of SMYD2. Two residues are of particular importance,
Y240 and Y258, which are highly conserved in the SMYD protein73, September 7, 2011 ª2011 Elsevier Ltd All rights reserved 1269
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ferases (Cheng et al., 2005; Wu et al., 2010). Residue Y258
orients the relative position of the 3-amino group of the acceptor
lysine of the p53 peptide substrate peptide within the lysine-
binding channel, whereas the hydroxyl group of residue Y240
participates in catalysis. Mutating residue Y240 abolishes the
methyltransferase activity of SMYD2 (Brown et al., 2006).
Together these residues and the electrostatic interactions they
form with the p53 substrate peptide, favor the transfer of the
donormethyl group from the cofactor SAM to the acceptor lysine
residue (Figure 5D). A similar series of electrostatic interactions
between protein lysine methyltransferases with their respective
substrates have been structurally observed (reviewed by Cheng
et al., 2005; Wu et al., 2010).
The crystal structures of various protein lysine methyltrans-
ferases have been determined in the absence and presence of
peptides derived from histone and nonhistone protein substrates
(reviewed by Cheng et al., 2005; Wu et al., 2010). In these struc-
tures, the acceptor lysine residue is bound in the lysine-binding
channel and is oriented toward the donor methyl group of the
cofactor. However, the structural basis of protein lysine methyl-
transferase inhibition has only been described for the G9a-like
protein GLP in complex with the small molecule BIX-01294 or
close derivatives thereof, including UNC0224 (Figure 6E) (Kubi-
cek et al., 2007; Chang et al., 2009; Liu et al., 2009). Similar to
AZ505, the BIX-01294molecule is bound in the substrate binding
groove of GLP, and the binding mode resembles the bound
conformation of a peptide derived from histone H3 (Chang
et al., 2009; Wu et al., 2010). As with SMYD2, a subtle conforma-
tional change is observed on inhibitor binding to GLP (Chang
et al., 2009). However, only a small portion of BIX-01294
occupies the lysine-binding channel (Figure 6E). In a follow up
study, lysine or methyl-lysine mimics were appended at C7 of
the quinazoline core of BIX-01294, which increased the potency
of these compounds (Chang et al., 2010). The crystal structures
of several of these analogs in complex with GLP showed that the
lysine mimic was positioned within the lysine-binding channel
(Figure 6E).
Occupancy of the lysine-binding channel and an adjacent
hydrophobic pocket in the inhibited conformation is a feature
common to both AZ505 and BIX-01294 analogs. However, the
identification and occupancy of a previously unknown third
inhibitor binding pocket is unique to SMYD2. The partially over-
lapping p53 peptide and AZ505 binding sites and an analysis
of the inhibitor binding mode suggest opportunities for improv-
ing the potency, selectivity and ligand efficiency of AZ505. First,
the 5-hydroxy-benzooxazinone group is well positioned to
make electrostatic interactions with additional residues lining
the lysine-binding channel. Replacing this group with a lysine
mimic is also conceivable. Second, the cyclohexyl group could
be altered to enhance electrostatic interactions within the
primary hydrophobic pocket. Third, the basic nitrogen linking
the dichlorophenethyl substituent is presumed to be protonated
at physiological pH, and interacts with the side chain of residue
N180. Alkylation of this nitrogen may adjust the charge density
to strengthen this interaction. Finally, the dichlorophenethyl
group occupying the secondary hydrophobic pocket might
be replaced with alternative aryl groups that are capable of form-
ing more extensive hydrophobic packing interactions with the1270 Structure 19, 1262–1273, September 7, 2011 ª2011 Elsevier Ltresidues lining this pocket. We observed clear and rational
SAR across this chemical series. Over 100 compounds were
tested and their inhibitory activities ranged from 0.14 mM
(AZ505) through >83 mM. Forty of these compounds had IC50
values <10 mM.
In conclusion, the structures presented here establish the
structural basis of nonhistone substrate methylation and selec-
tive pharmalogical inhibition of SMYD2. The discovery and
biophysical characterization of AZ505, a potent and highly selec-
tive inhibitor of SMYD2, provides an invaluable tool to probe the
cell biology of SMYD2 and to support the development of novel
cancer therapies.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification
The gene encoding full-length human SMYD2 (residues 1–433) was codon
optimized for Escherichia coli and subcloned into a proprietary Gateway
adapted pET vector containing an N-terminal TEV-cleavable 6xHis-tag. The
recombinant protein was expressed in E. coliBL21 Star (DE3) cells in TBmedia
supplemented with 25 mg/ml tetracycline, 50 mg/ml kanamycin, and 50 mM
ZnCl2. Bacterial cultures were grown at 37
C until the OD600 reached 0.6 at
which point 0.1 mM IPTG was added. The cultures were grown for an addi-
tional 24 hr at 18C and harvested by centrifugation.
Cell pellets were resuspended in buffer A (40 mM Tris [pH 8.0], 300 mM
NaCl, 20 mM imidazole, and 5 mM b-mercaptoethanol) supplemented with
complete EDTA-free protease inhibitor tablets and 2.5 U/ml benzonase. Cells
were lysed by two passes through a Constant Systems Basic Z, and the cell
lysate clarified by centrifugation. The cell lysate was loaded onto a Ni-NTA
column equilibrated in buffer A, and eluted with imidazole. The His-tag was
cleaved with TEV protease during dialysis into buffer B (20 mM Tris [pH 8.0],
20 mM NaCl, 25 mM imidazole, and 5 mM b-mercaptoethanol) overnight at
4C. Uncleaved SMYD2 and TEV protease were separated from the cleaved
protein by passing the sample over a second Ni-NTA column equilibrated in
buffer B. The protein was further purified by ion exchange chromatography,
followed by gel filtration using a Superdex S75 size exclusion column equili-
brated in 20 mM Tris (pH 8.0), 100mMNaCl, and 1mM TCEP. Protein contain-
ing fractions were pooled, concentrated, and stored at80C for biochemical
characterization and crystallization.
HTS and Enzymatic Activity Assays
SMYD2was expressed in insect cells and purified as described elsewhere (Wu
et al., 2011). AlphaScreen technology was used to screen our chemical library
for small molecule inhibitors of SMYD2 (Eglen et al., 2008). Methylation (12 ml)
reactions were carried out in TDT buffer (50 mM Tris-HCl [pH 9.0], 2 mM DTT,
and 0.01% Tween 20) at room temperature using 1.25 nM SMYD2 protein,
200 nM SAM, and 100 nM biotinylated p53 peptide substrate (Biotin-
aminohexanoyl-GSRAHSSHLKSKKGQSTSRH) in low volume 384-well plates.
Following a 75min incubation period, reactions were quenched by the addition
of 5 ml of detection solution (20 mM HEPES [pH 7.4], 1.7 mg/ml BSA, 340 mM
NaCl, 680 mM SAH, 0.04 mg/ml Streptavidin-coated AlphaScreen donor, and
Protein A-coated acceptor beads), and 1.0 nM of a custom p53K370me1 poly-
clonal antibody. Reaction plates were incubated overnight in the dark at room
temperature, and read using an Envision 2101Multi-label Reader. Compounds
showing >50% inhibition of SMYD2 were nominated for concentration dose-
response determination, and were also subjected to an artifact assay. Seven
compound concentrations were selected beginning at 30 mM with six half-
log dilution steps. The artifact assay conditions were identical to those in the
SMYD2 enzymatic activity assay, except for the absence of SMYD2 protein
and the presence of 1 nMmethylated p53 peptide. IC50 values were calculated
from dose-response data using in-house software.
Radiometric Assays
Orthogonal radiometric filter binding and SPA assays were developed to eval-
uate the authenticity of the primary screening hits. Filter binding assays were
performed at room temperature in TDT buffer. Reaction mixtures (110 ml)d All rights reserved
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well) were transferred to a 96-well reaction plate and incubated for 90 min.
Aliquots (100 ml) of each reaction mixture were transferred to a pretreated
96-well MultiScreenHTS FB plate and vacuum dried. The reaction wells
were washed three times with TDT buffer containing 100 mM SAH, resus-
pended with 50 ml MicroScint solution, and read with a TopCount 384 radioac-
tivity counter. SPA assays were run under similar experimental conditions with
low volume 384-well plates, except the pH of the buffer was reduced to
pH 8.5. The enzymatic reaction was quenched by the addition of SAH and
Streptavidin-coated SPA beads in 20 mM HEPES (pH 7.4) to each well.
Following an overnight incubation at room temperature, reaction plates were
read using a TopCount 384 radioactivity counter.
Ratio Test
The SPA assay ratio test compares the IC50 values determined from rapid
reaction conditions using a 10-fold excess of SMYD2 protein to the IC50 values
determined using standard reaction conditions following a 30 min preincuba-
tion with compound. For compounds that induce protein aggregation, we
expect a time-dependent decrease in the IC50 value following compound
preincubation and an enzyme concentration-dependent increase in IC50 value,
whereas the IC50 values for compounds that do not induce protein aggregation
should remain constant. A ratio test value >2 suggests that the compound
induces protein aggregation, unless its IC50 is <1 mM.
Kinetics
SMYD2was expressed in insect cells and purified as described elsewhere (Wu
et al., 2011). To understand the mechanism of inhibition, fixed compound
concentrations ranging from 16 to 1000 nM were added to 96-well reaction
plates containing 5 nM SMYD2 with variable amounts of [3H]-SAM (12.5–
400 nM) in the presence of a saturating concentration of p53 peptide
(20 mM) or variable amounts of p53 peptide (0.6–20 mM) and a saturating
concentration of [3H]-SAM (800 nM). Reactions were carried out for 15 min
at room temperature, transferred to a 96-well MultiScreenHTS FB plate con-
taining 100 ml of 2% TCA, and incubated for 10 min. Reaction mixtures were
dried under vacuum, washed five times with 2% TCA and 100% methanol,
resuspended with MicroScint solution, and read with a TopCount 384 radioac-
tivity reader. Untransformed data were fit with Michaelis-Menten equations,
and double-reciprocal plots were generated from these parameters.
ITC
ITC experiments were conducted using a Microcal ITC200 at 23C in 25 mM
Tris (pH 8.5), 50 mM NaCl and 2% DMSO. Approximately 300 ml of a 15 mM
SMYD2 protein solution was loaded into the sample cell, and a 200 mMsolution
of AZ505 solubilized in DMSO was loaded into the injection syringe. Eight 4 ml
injections of compound were sequentially added to the sample cell, producing
a final compound-to-protein molar ratio of approximately 1.4:1. We find that
fewer larger volume injections improve the signal-to-noise ratio for low
enthalpy, low solubility compounds without compromising data quality. Ther-
modynamic parameters N (stoichiometry), Ka (association constant), and DH

(enthalpic change) were obtained by nonlinear least-square fitting using Origin
software.
Crystallization
SMYD2 expressed and purified from E. coli was used for crystallization
studies. Primary crystallization trials were carried out with in-house sparse
matrix screens using 12 mg/ml protein solution containing 0.5 mM SAM at
20C. Initial SMYD2 protein crystals were obtained by hanging drop vapor
diffusion using a reservoir solution of 20% PEG 3350, 0.1 M Tris-HCl
(pH 7.5), and 5% ethanol. Crystals grown under these conditions were used
to generate a seed stock. Following optimization of crystal growth conditions,
protein crystals suitable for data collection were grown by mixing 0.7 ml of
reservoir solution, 1 ml of protein solution at 3 mg/ml containing 500 mM
SAM, and 0.3 ml of the seed stock at 20C. Crystals typically appeared within
3 days and achieved their full size in 1 week. SMYD2 crystals in complex with
AZ505 or the peptide derived from the regulatory domain of p53 (residues
366-SSHLKSKKGQSTS-378) were generated by cocrystallization. All crystals
were vitrified in liquid nitrogen using a cryoprotectant solution consisting of
a 4:1 ratio of reservoir solution and L-(+)-2,3-butanediol.Structure 19, 1262–12Crystallography
All X-ray diffraction data were collected at cryogenic temperature using
synchrotron radiation at beam lines ID 14-4 and ID 23-1 at the ERSF (Grenoble,
France). Diffraction data was processed with XDS (Kabsch, 2010) and
scaled using SCALA (CCP4, 1994), as implemented in the autoPROC routines
from Global Phasing (Vonrhein et al., 2011). These crystals belong to the
tetragonal space group I4 and contain one molecule per asymmetric unit
(Table 1).
Phase information was derived from a single wavelength anomalous diffrac-
tion (SAD) experiment collected at the peak of the zinc X-ray fluorescence
spectrum. The program SHARP (Vonrhein et al., 2007) was used to locate
and refine the positions of three zinc sites (Table 1). Although this data set
only extended to 3 A˚ resolution, the hand of the molecule could be readily
established by unambiguous differences observed in experimental electron
density maps calculated from both phases of the heavy atom enantiomorphs.
A second lower resolution data set was collected at the peak of the selenium
X-ray fluorescence spectrum. The positions of the zinc atoms were used to
locate 11 of 13 partially occupied selenium sites with SHARP. The clarity of
experimental electron density map was further improved with density modifi-
cation using a solvent fraction of 58% followed by temperature factor sharp-
ening (Table 1). The program Buccaneer was then used to automatically build
50% of the protein backbone, including some side chains (CCP4, 1994). The
model was completed by sequential rounds of manual rebuilding using Coot
(Emsley et al., 2010) andmacromolecular refinement using BUSTER (Bricogne
et al., 2009).
The SMYD2 structures with AZ505 and both p53 peptides were solved by
molecular replacement. The difference density map for AZ505-bound
SMYD2 unambiguously showed connected difference density with the
expected molecular features for this compound. However, the difference
density maps for SMYD2 in complex with both p53 peptides only showed con-
nected difference density for the central region of the p53 peptide as the
N- and C-termini portions of the peptide were not visible in the electron density
maps. Sequential rounds of model building and refinement produced models
for SMYD2 that contain all residues except for the first four N-terminal resi-
dues. The final refinement statistics are shown in Table 1. All figures were
prepared using PyMOL.ACCESSION NUMBERS
The coordinates and structure factors have been deposited in the Protein Data
Bank with accession codes: 3S7J (SMYD2 with SAM), 3S7B (SMYD2 with
SAM and AZ505), 3S7F (SMYD2 with SAM and the p53 peptide substrate),
and 3S7D (SMYD2 with SAM and the monomethylated p53 product peptide),
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